newsantibody-drug conjugatesDatopotamab Deruxtecan
Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results
By MedXY|Jan 9, 2026
The final TROPION-Breast01 analysis confirms datopotamab deruxtecan’s superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC cro
